KHK7580
7580-201
Phase 3 small_molecule completed
Quick answer
KHK7580 for Secondary Hyperparathyroidism is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Secondary Hyperparathyroidism
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed